Amylin and Lilly Seek Expanded Use of BYETTA

Amylin Pharmaceuticals, Inc. AMLN and Eli Lilly and Company LLY today announced that a supplemental New Drug Application has been submitted to the U.S. Food and Drug Administration for the expanded use of BYETTA injection as an add-on therapy to basal insulin, with or without metformin and/or a thiazolidinedione in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.